poisar

Stocks · News reference

Olema Oncology Announces Preclinical Data for KAT6A Degraders

Fiscal.ai

Olema Oncology reported preclinical data on its selective KAT6A degraders in ER+/HER2- breast cancer models, which will be presented at the 38th EORTC-NCI-AACR Symposium.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Olema Oncology, Inc. (OLMA)

    Filed: 2026-11-12 AccNo: 0001193125-26-458572 Size: 751 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

  2. Globenewswire IncNa

    Olema Oncology Announces Corporate Name Change

    Olema Pharmaceuticals, Inc. has officially changed its corporate name to Olema Oncology, Inc., effective November 12, 2026. The company's stock will continue trading on Nasdaq under ticker symbol OLMA. The clinical-stage biopharmaceutical company is advancing its lead product candidate palazestrant (OP-1250) through two Phase 3 trials, with top-line data from the OPERA-01 trial expected in Q1 2027.